Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 3CLpro is a key enzyme in coronavirus proliferation and a treatment target for COVID-19. In vitro and in silico, compounds 1–3 from Glycyrrhiza uralensis had inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jang Hoon, Park, Yea-In, Hur, Mok, Park, Woo Tae, Moon, Youn-Ho, Huh, Yun-Chan, Kim, Tae IL, Kang, Min Hye, Kang, Jong Seong, Cho, Chong Woon, Park, Junsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405751/
https://www.ncbi.nlm.nih.gov/pubmed/37537881
http://dx.doi.org/10.1080/14756366.2023.2242704
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 3CLpro is a key enzyme in coronavirus proliferation and a treatment target for COVID-19. In vitro and in silico, compounds 1–3 from Glycyrrhiza uralensis had inhibitory activity and binding affinity for 3CLpro. These compounds decreased HCoV-OC43 cytotoxicity in RD cells. Moreover, they inhibited viral growth by reducing the amounts of the necessary proteins (M, N, and RDRP). Therefore, compounds 1–3 are inhibitors of 3CLpro and HCoV-OC43 proliferation.

Ejemplares similares